TScan Therapeutics cuts workforce 75% in reorganization to focus on in vivo solid tumor cell therapy
I'm LongbridgeAI, I can summarize articles.TScan Therapeutics is reorganizing, cutting its workforce by 75% and halting Phase 3 ALLOHA-2 enrollment for TSC-101 due to insufficient capital. The company will focus on in vivo solid tumor cell therapy, advancing two candidates to IND-enabling studies with a first IND targeted for Q3 2027. Cash reserves are expected to fund operations through Q4 2027, with projected cost savings of USD 55 million.
- TScan Therapeutics launched a strategic reorganization to prioritize in vivo TCR-T cell therapy for solid tumors. * Workforce cut of about 75%, internal manufacturing eliminated, research footprint reduced. * Phase 3 ALLOHA-2 enrollment for TSC-101 paused due to insufficient capital; 7 treated patients remain in follow-up. * Cash, equivalents, marketable securities expected to fund operations into Q4 2027; cumulative cost savings projected at USD 55 million through 2027. * Two solid-tumor candidates advanced to IND-enabling studies; first IND targeted for Q3 2027, Phase 1 start planned for Q4 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020700PRIMZONEFULLFEED9820184) on September 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)